StockData
Reviva Pharmaceuticals Holdings, Inc. logo

Reviva Pharmaceuticals Holdings, Inc. (RVPH) stock

RVPHOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 2/30
$0.45−0.02 (-4.36%)

Close on Oct 19, 2026Market cap $5.94MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026

Valuation

Market cap
$5.94M
P/E ratio
–
Price to sales
–
Price to book
0.45
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$11.31M
EPS, diluted
-$1.40
Book value per share
$0.99
Diluted shares
13M

Trading

Next earnings
Nov 12, 2026 (estimated, during market hours)
Previous close
$0.47
Open
$0.47
Day's range
$0.45 – $0.50
Volume
34,085
Average volume (20 days)
28,254

Market cap history

Month-end market cap since 2020, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodRVPHS&P 500DifferenceRVPH per yearS&P 500 per year
1 month-6.2%+0.6%−6.9 pts
3 months-20.4%+3.4%−23.7 pts
Year to date-91.9%+13.3%−105.2 pts
1 year-96.1%+16.6%−112.7 pts
3 years-99.4%+86.4%−185.8 pts-81.8%+23.1%
5 years-99.3%+81.9%−181.2 pts-63.5%+12.7%

Eight years at a glance

Fiscal years 2018 to 2025 and trailing twelve months, USD

Operating income

-$11.88M

Net income

-$11.31M

EPS, diluted

-$1.40
Reported periodTrailing twelve months

Press releases

Releases Reviva Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Reviva Pharmaceuticals

Pharmaceutical Preparations

Reviva Pharmaceuticals Holdings, Inc. is a pharmaceutical company that focuses on the clinical development of therapeutic drug candidates. Its primary product candidate in development is brilaroxazine, a chemical compound under evaluation for the treatment of patients with schizophrenia. The company conducts clinical trials to assess the safety and efficacy of this candidate. Because Reviva is currently engaged in drug research and clinical trials, the text identifies no commercial operating segments, and its prospective users are individuals diagnosed with schizophrenia.

Company profile, executives and history

Reviva Pharmaceuticals stock: common questions

What is Reviva Pharmaceuticals's stock price?

RVPH closed at $0.45 on Oct 19, 2026, down 4.36% on the day.

What is Reviva Pharmaceuticals's market cap?

Reviva Pharmaceuticals was worth $5.94M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is RVPH's P/E ratio?

Reviva Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.40), so it has no meaningful P/E ratio.

Does Reviva Pharmaceuticals pay a dividend?

No. Reviva Pharmaceuticals has not paid a cash dividend over the last twelve months.

When does Reviva Pharmaceuticals report earnings next?

Reviva Pharmaceuticals is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.

How has RVPH stock performed over the past year?

Including dividends, RVPH returned -96.1% over the past year, against +16.6% for the S&P 500.

Who are Reviva Pharmaceuticals's competitors?

Companies most similar to Reviva Pharmaceuticals by business, industry and size include NERV, MPLT, KTTA, COGT, OVID.

See a number that looks wrong?